241 related articles for article (PubMed ID: 38014143)
41. Aβ42-mediated proteasome inhibition and associated tau pathology in hippocampus are governed by a lysosomal response involving cathepsin B: Evidence for protective crosstalk between protein clearance pathways.
Farizatto KLG; Ikonne US; Almeida MF; Ferrari MFR; Bahr BA
PLoS One; 2017; 12(8):e0182895. PubMed ID: 28797057
[TBL] [Abstract][Full Text] [Related]
42. Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.
Pchelina S; Emelyanov A; Baydakova G; Andoskin P; Senkevich K; Nikolaev M; Miliukhina I; Yakimovskii A; Timofeeva A; Fedotova E; Abramycheva N; Usenko T; Kulabukhova D; Lavrinova A; Kopytova A; Garaeva L; Nuzhnyi E; Illarioshkin S; Zakharova E
Neurosci Lett; 2017 Jan; 636():70-76. PubMed ID: 27780739
[TBL] [Abstract][Full Text] [Related]
43. A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology.
Chedid J; Labrador-Garrido A; Zhong S; Gao J; Zhao Y; Perera G; Kim WS; Halliday GM; Dzamko N
J Biol Chem; 2022 Aug; 298(8):102260. PubMed ID: 35841928
[TBL] [Abstract][Full Text] [Related]
44. Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.
Stojkovska I; Wani WY; Zunke F; Belur NR; Pavlenko EA; Mwenda N; Sharma K; Francelle L; Mazzulli JR
Neuron; 2022 Feb; 110(3):436-451.e11. PubMed ID: 34793693
[TBL] [Abstract][Full Text] [Related]
45. Lipids as
Ikenaka K; Suzuki M; Mochizuki H; Nagai Y
Front Neurosci; 2019; 13():693. PubMed ID: 31333408
[TBL] [Abstract][Full Text] [Related]
46. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
47. Distinct alpha-Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH-SY5Y cells.
Pantazopoulou M; Brembati V; Kanellidi A; Bousset L; Melki R; Stefanis L
J Neurochem; 2021 Mar; 156(6):880-896. PubMed ID: 32869336
[TBL] [Abstract][Full Text] [Related]
48. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.
Parnetti L; Chiasserini D; Persichetti E; Eusebi P; Varghese S; Qureshi MM; Dardis A; Deganuto M; De Carlo C; Castrioto A; Balducci C; Paciotti S; Tambasco N; Bembi B; Bonanni L; Onofrj M; Rossi A; Beccari T; El-Agnaf O; Calabresi P
Mov Disord; 2014 Jul; 29(8):1019-27. PubMed ID: 24436092
[TBL] [Abstract][Full Text] [Related]
49. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
[TBL] [Abstract][Full Text] [Related]
50. Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links.
Moors T; Paciotti S; Chiasserini D; Calabresi P; Parnetti L; Beccari T; van de Berg WD
Mov Disord; 2016 Jun; 31(6):791-801. PubMed ID: 26923732
[TBL] [Abstract][Full Text] [Related]
51. Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy.
Kuo SH; Tasset I; Cheng MM; Diaz A; Pan MK; Lieberman OJ; Hutten SJ; Alcalay RN; Kim S; Ximénez-Embún P; Fan L; Kim D; Ko HS; Yacoubian T; Kanter E; Liu L; Tang G; Muñoz J; Sardi SP; Li A; Gan L; Cuervo AM; Sulzer D
Sci Adv; 2022 Feb; 8(6):eabm6393. PubMed ID: 35138901
[TBL] [Abstract][Full Text] [Related]
52. The Emerging Role of the Lysosome in Parkinson's Disease.
Navarro-Romero A; Montpeyó M; Martinez-Vicente M
Cells; 2020 Nov; 9(11):. PubMed ID: 33147750
[TBL] [Abstract][Full Text] [Related]
53. Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates.
Bae EJ; Yang NY; Lee C; Kim S; Lee HJ; Lee SJ
Cell Death Dis; 2015 Oct; 6(10):e1901. PubMed ID: 26448324
[TBL] [Abstract][Full Text] [Related]
54. Cathepsin-mediated regulation of alpha-synuclein in Parkinson's disease: a Mendelian randomization study.
Lin L; Wu Z; Luo H; Huang Y
Front Aging Neurosci; 2024; 16():1394807. PubMed ID: 38872630
[TBL] [Abstract][Full Text] [Related]
55. Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.
Dermentzaki G; Dimitriou E; Xilouri M; Michelakakis H; Stefanis L
PLoS One; 2013; 8(4):e60674. PubMed ID: 23580063
[TBL] [Abstract][Full Text] [Related]
56. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M; Brekk OR; Stefanis L
Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
[TBL] [Abstract][Full Text] [Related]
57. Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous α-synuclein fibrils.
Tsujimura A; Taguchi K; Watanabe Y; Tatebe H; Tokuda T; Mizuno T; Tanaka M
Neurobiol Dis; 2015 Jan; 73():244-53. PubMed ID: 25466281
[TBL] [Abstract][Full Text] [Related]
58. The Consequences of GBA Deficiency in the Autophagy-Lysosome System in Parkinson's Disease Associated with GBA.
Pradas E; Martinez-Vicente M
Cells; 2023 Jan; 12(1):. PubMed ID: 36611984
[No Abstract] [Full Text] [Related]
59. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
60. The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics.
Rubilar JC; Outeiro TF; Klein AD
Brain; 2024 Mar; ():. PubMed ID: 38437875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
